(MYGN) Myriad Genetics, Inc. ANSOFF Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(MYGN) Myriad Genetics, Inc. Complete Analysis Pack
Explore the Complete Growth Strategy Behind the Preview
This Myriad Genetics, Inc. Ansoff Matrix Analysis maps growth options across market penetration, market development, product development, and diversification to help with strategy, investing, or planning; this page includes a real preview of the analysis so you can judge style and substance. Purchase the full version to get the complete, ready-to-use company-specific Ansoff Matrix report.
Market Penetration
MyRisk U.S. adoption
MyRisk Hereditary Cancer Test is already in the U.S. oncology and genetics referral flow, so the penetration play is to win more orders from the same channel, not change the product mix. That means higher test volume, better fixed-cost absorption, and more share in an existing inherited-cancer market. In Myriad Genetics, Inc.'s 2025 reporting, this matters because U.S. adoption is the fastest path to grow revenue without adding launch risk.
GeneSight prescriber growth
GeneSight Psychotropic targets depression, anxiety, and ADHD medication selection, so prescriber growth is the core market-penetration lever in behavioral health and primary care. Deeper clinician adoption and more repeat testing can lift test volume without changing the product mix.
Myriad Genetics said GeneSight reached over 1 million patient tests cumulatively, which shows real clinician traction. More repeat use should improve revenue per prescriber and strengthen share in the same prescribing base.
Women's health screening share
Prequel Prenatal Screen and Foresight Carrier Screen already fit the U.S. women’s health market, which is tied to roughly 3.6 million annual births. Penetration comes from more orders in OB-GYN and maternal-fetal medicine clinics, not from a new market. Even a small share gain in these high-volume settings can lift test volume fast.
Oncology prognostic test uptake
Prolaris in prostate cancer and EndoPredict in breast cancer sit in existing urology and breast oncology pathways, so Myriad Genetics, Inc. is pushing deeper clinician ordering, not new disease areas. In 2025, the American Cancer Society estimated 313,780 new prostate cases and 316,950 invasive breast cancers in the U.S., giving the company large, recurring test pools.
- Grow orders inside current care pathways
- Target urologists and breast oncologists
- Use existing evidence to raise repeat use
Companion diagnostic utilization
BRACAnalysis CDx and MyChoice CDx already sit in oncology workflows for metastatic breast, ovarian, pancreatic, and prostate cancer, plus ovarian HRD testing. Myriad Genetics can grow market penetration by increasing test use at diagnosis and at treatment change points, where companion diagnostics guide therapy choice.
This is a workflow win, not a new market. As more oncologists use biomarker-led care, Myriad Genetics can lift share in an installed base that is already familiar with the tests and their clinical value.
- Supports treatment selection in oncology
- Targets metastatic and HRD-linked cancers
- Expands share through routine use
Myriad’s Growth: More Tests Through Existing U.S. Care Pathways
Market penetration for Myriad Genetics, Inc. means pushing more tests through the same U.S. care pathways, especially MyRisk, GeneSight, and women’s health screens. In 2025, the U.S. still offered large pools: 3.6 million annual births and 313,780 new prostate cancer cases. More repeat use and clinician adoption can lift volume without new launches.
| Test | 2025 U.S. pull | Penetration lever |
|---|---|---|
| GeneSight | 1M+ cumulative tests | More prescribers |
| MyRisk | Large oncology referral base | More orders |
What is included in the product
Detailed Word Document
Provides a clear Ansoff Matrix framework for analyzing Myriad Genetics, Inc.’s growth strategy across existing and new products and markets
Editable Excel File
Provides a quick Ansoff Matrix view for Myriad Genetics, Inc. to simplify growth strategy decisions.
Reference Sources
Consolidates reputable Myriad Genetics sources to verify Ansoff Matrix growth paths quickly and make strategy assumptions traceable.
Market Development
International test menu expansion
Myriad Genetics can push its existing test menu into more countries without changing the core assays, which fits market development. The company already sells across the U.S. and international markets, so the upside is wider reach, not new product risk.
That matters because Myriad’s 2025 revenue base was still built on the same branded tests, so each new geography can add volume with limited R&D spend. One clean example: the same hereditary cancer and prenatal tests can be sold through local labs, payers, and physician networks in Europe and Asia.
For Myriad Genetics, this is a low-change, high-reach move: expand distribution, clear local reimbursement, and keep the menu intact. If international penetration rises even a few points, test volumes can grow faster than fixed costs.
Illumina channel expansion
Myriad Genetics, Inc.'s alliance with Illumina, Inc. supports market development by widening germline and tumor testing access beyond Myriad Genetics' direct sales channels. It can use Illumina's installed sequencing base and partner network, which lowers market entry friction and speeds reach into labs that already run next-gen sequencing workflows. That matters because platform access is often the fastest path to new geographies and accounts.
Intermountain network expansion
Myriad Genetics, Inc. uses its Intermountain Precision Genomics tie-up to push into new health-system and regional referral channels, expanding access to germline and somatic tumor testing. Intermountain Health operates 33 hospitals, giving Myriad a wider clinical funnel and a stronger route into large, integrated care networks.
New specialty accounts
Market development for Myriad Genetics means selling its existing oncology, women’s health, and mental health tests into new physician groups and health systems. New specialty account wins expand reach without new-product spend, so they can lift revenue faster than R&D. In FY2025, this model matters because the same test menu can be monetized across more sites of care.
- 3 core test areas
- More accounts, same menu
- Lower launch cost
International clinical adoption
Myriad Genetics, Inc. can push MyRisk, GeneSight, and Prequel into non-U.S. clinics as the same assays in a new market. This fits precision medicine demand, which keeps rising as countries expand carrier screening, oncology risk testing, and pharmacogenomics adoption.
International uptake is a scale play, not a product redesign. In FY2025, the key signal is that the addressable pool is far larger than Myriad Genetics, Inc.'s U.S.-only base, so even modest penetration can lift test volume and recurring assay revenue.
- Same tests, new geography
- Targets growing precision medicine demand
- Uses existing clinical evidence
Myriad’s Growth Play: Same Tests, Wider Reach
Myriad Genetics’ market development is about taking the same FY2025 test menu into new geographies and care networks, so growth comes from reach, not new assay risk. The Illumina link and Intermountain’s 33 hospitals widen access to oncology, women’s health, and mental health tests with limited launch cost.
| Lever | Data |
|---|---|
| Intermountain Health | 33 hospitals |
| Product set | Same FY2025 test menu |
| Growth path | More sites, same assays |
Full Version Awaits
Myriad Genetics, Inc. Reference Sources
This is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.
Product Development
Oncology assay breadth
Myriad Genetics already sells at least 6 oncology assays, including MyRisk, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, and Precise Tumor, so product development here means widening the menu for the same customers. In FY2025, that matters because the company can lift test mix and repeat use without changing its core oncology buyer base. The play is to add new assays or larger panels, not chase a new market.
BRCA and HRD extension
Myriad Genetics, Inc. can extend its BRCA and HRD testing deeper into oncology by adding more tumor types and therapy-linked use cases. That fits product development because it builds on existing cancer diagnostics rather than entering new markets. In a 2025 oncology base where BRCA and HRD already guide PARP inhibitor use, broader test panels can raise clinical reach without changing the core customer set.
RNA-based prognostic expansion
Prolaris uses a 46-gene cell-cycle score and EndoPredict uses a 12-gene panel, so Myriad Genetics, Inc. can extend RNA-based prognostics without rebuilding the lab workflow. Adding new prostate and breast cancer risk tools would deepen decision support for the same urologists and oncologists already using these tests. That can raise test breadth per clinician and improve uptake across a shared installed base.
Prenatal panel enhancement
Prenatal panel enhancement is a product-depth play: Prequel and Foresight already cover prenatal and carrier screening, so Myriad Genetics, Inc. can add more conditions, broader panel content, and sharper reports for women’s health providers and expectant parents. With about 3.6 million U.S. births a year, the demand base stays large.
- Expand condition coverage
- Refine report clarity
- Sell to current provider channels
GeneSight content expansion
GeneSight content expansion fits product development: the test already uses DNA genotyping to guide psychotropic drug choice, and adding more pharmacogenomic markers or stronger clinical decision support can raise its utility without changing the core behavioral health buyer. In the U.S., more than 50% of patients with major depression do not respond to the first antidepressant, so better prescribing support has clear value.
- Uses existing behavioral health base
- Adds pharmacogenomic depth
- Improves prescribing decisions
- Targets high unmet need
Myriad’s Installed Base Fuels Repeat-Test Growth
Product development at Myriad Genetics, Inc. means adding new assays and stronger panels for the same oncology, prenatal, and behavioral health customers. In FY2025, this fits Myriad Genetics, Inc.’s installed base: MyRisk, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Precise Tumor, Prequel, Foresight, and GeneSight already support repeat use.
| Area | FY2025 signal |
|---|---|
| Oncology | 6+ assays |
| Prenatal | 3.6M U.S. births |
| Behavioral health | 50%+ first-try nonresponse |
Diversification
Germline and somatic integration
Myriad Genetics, Inc. already serves two testing lines: germline and somatic tumor testing. Folding both into one precision medicine offer lets Myriad Genetics, Inc. sell more combined test panels and move into new diagnostic service mixes. That matters in a market where one cancer case can need both inherited-risk and tumor-profiling data for treatment choices.
Partner-enabled diagnostic services
Myriad Genetics, Inc. can diversify by co-delivering diagnostic services with Illumina and Intermountain Precision Genomics, not just by selling stand-alone tests. That model opens access to hospitals and labs through partner channels and fits a service-led Ansoff diversification move. One offer can reach two care networks at once, widening adoption without building every route alone.
Precision medicine workflow offerings
Myriad Genetics, Inc. can use diversification to turn its oncology, women’s health, and mental health tests into one precision medicine workflow suite, shifting from stand-alone assays to integrated care support. That model can raise clinician stickiness and widen revenue per patient by embedding results, risk insights, and follow-up guidance into daily care paths.
Somatic tumor service expansion
Precise Tumor and MyChoice CDx show Myriad Genetics, Inc. can already support tumor testing, so diversification can widen that base into molecular pathology service lines. The move targets broader tumor decision support, not a single assay, and it can lift test utility across more oncology workflows.
This is an adjacent diversification play in the Ansoff Matrix: same cancer focus, wider service scope. It can deepen share in a larger lab market if Myriad Genetics, Inc. pairs assay data with interpretation, reporting, and clinician support.
- Build beyond one assay
- Expand into pathology services
- Sell broader decision support
Multi-indication genomics platform
Myriad Genetics, Inc. already spans oncology, reproductive health, and mental health, so a multi-indication genomics platform is a true diversification play. By linking test menus, data, and clinician workflow across these three care areas, Company Name can widen adjacent-market reach and raise the lifetime value of each customer.
This matters because Myriad Genetics, Inc. has built clinical franchises in cancer risk, prenatal screening, and pharmacogenomics, giving it a broader base than a single-indication peer. The upside is cross-selling, shared lab infrastructure, and more usable genetic data across more than one disease area.
- Three care areas already in place
- Cross-sell across oncology, reproductive, psychiatry
- Broader base lowers single-market risk
- Shared data can lift platform value
Myriad Genetics Expands Into a Broader Precision-Medicine Platform
Myriad Genetics, Inc. can use diversification to move from separate tests into a broader precision-medicine platform across oncology, women’s health, and mental health. That widens revenue per patient, lifts cross-sell, and reduces reliance on any one assay line.
| Area | Use |
|---|---|
| Oncology | Tumor profiling and decision support |
| Women’s health | Risk screening and follow-up |
| Mental health | Pharmacogenomic guidance |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.